[Current therapy of prostate carcinoma]

Area of Science:

• Oncology
• Urology

Context:

• Prostatic carcinoma (PCA) presents diagnostic and therapeutic challenges despite extensive research.
• Early detection of PCA is enhanced by prostate-specific antigen (PSA) testing and its advancements.

Purpose:

• To review the current controversies in the diagnosis and treatment of prostatic carcinoma.
• To highlight the role of PSA in early PCA detection.
• To discuss evolving therapeutic strategies for organ-confined and progressive PCA.

Summary:

• Prostate-specific antigen (PSA) and its subtests facilitate earlier diagnosis of prostate cancer.
• There is a lack of rigid therapeutic guidelines for PCA, necessitating individualized treatment plans.
• Novel therapeutic concepts for organ-confined and progressive disease prioritize quality of life improvements.

Impact:

• Improved early detection rates for prostate cancer through PSA advancements.
• Shift towards patient-centered, quality-of-life-focused treatment strategies for PCA.
• Potential for better management of organ-confined and progressive prostate cancer stages.